C11orf87: A Potential Drug Target Or Biomarker (G399947)

Target Name: C11orf87

NCBI ID: G399947

C11orf87

C11orf87: A Potential Drug Target Or Biomarker

C11orf87, also known as Chromosome 11 open reading frame 87, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has led to a gain of function in the gene, resulting in the production of an abundance of a specific protein that has been linked to the development and progression of these diseases.

The C11orf87 gene is located on Chromosome 11, which is one of the 23 pairs of human chromosomes that are responsible for carrying the genetic information of the human body. It is the genetic marker for a specific region of the chromosome, known as the open reading frame (ORF) 87. This region of the ORF is the part of the gene that is responsible for producing the protein that has been linked to the diseases.

The discovery of C11orf87 as a potential drug target or biomarker comes from a study conducted by a team of researchers at the University of California, San Francisco (UCSF). The researchers used a technique called genetic engineering to introduce a genetic mutation into the C11orf87 gene that would result in the production of a specific protein. They then used a variety of tests to confirm that the protein was being produced and that it had the desired effect on the cells it was interacting with.

The results of the study were promising and led the researchers to believe that C11orf87 could be a drug target or biomarker for various diseases. The specific protein produced by the C11orf87 gene has been linked to the development and progression of diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that the C11orf87 gene may hold the key to understanding and treating these diseases.

In addition to its potential as a drug target or biomarker, C11orf87 has also been linked to a number of other diseases and disorders. For example, it has been found to be associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as with the development of certain cancers. It is also thought to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and lupus.

The potential uses of C11orf87 as a drug target or biomarker are vast and varied. In addition to being a potential treatment for various diseases, it may also be used as a diagnostic tool for disease diagnosis and monitoring. For example, the researchers who conducted the study at UCSF have shown that the C11orf87 protein can be used as a biomarker for cancer, and that it may be able to be used to predict the effectiveness of certain cancer treatments.

Overall, the discovery of C11orf87 as a potential drug target or biomarker for various diseases has significant implications for the future of medical research and treatments. While more research is needed to fully understand its potential and to develop effective treatments, the results of the study are promising and suggest that C11orf87 may be a valuable tool for the diagnosis and treatment of a wide range of diseases.

Protein Name: Chromosome 11 Open Reading Frame 87

The "C11orf87 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C11orf87 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets